BlackRock
CRBP icon

BlackRock’s Corbus Pharmaceuticals CRBP Stock Holding History

BlackRock’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
1,331,135
+1,059,499
+390% +$10M ﹤0.01% 3560
2026
Q1 		$2.55M Buy
271,636
+3,590
+1% +$30.2K ﹤0.01% 4063
2025
Q4 		$2.18M Buy
268,046
+41,148
+18% +$508K ﹤0.01% 4093
2025
Q3 		$2.87M Sell
226,898
-125,511
-36% -$1.19M ﹤0.01% 3985
2025
Q2 		$2.43M Sell
352,409
-493,653
-58% -$3.59M ﹤0.01% 4011
2025
Q1 		$4.49M Sell
846,062
-27,312
-3% -$241K ﹤0.01% 3686
2024
Q4 		$10.3M Buy
873,374
+70,653
+9% +$1.18M ﹤0.01% 3412
2024
Q3 		$16.6M Buy
802,721
+41,354
+5% +$2.12M ﹤0.01% 3159
2024
Q2 		$34.5M Buy
761,367
+540,505
+245% +$22.7M ﹤0.01% 2648
2024
Q1 		$8.67M Buy
220,862
+139,797
+172% +$3.45M ﹤0.01% 3412
2023
Q4 		$490K Sell
81,065
-119
-0.1% -$639 ﹤0.01% 4427
2023
Q3 		$547K Sell
81,184
-780
-1% -$5.4K ﹤0.01% 4400
2023
Q2 		$643K Buy
81,964
+9,807
+14% +$88.2K ﹤0.01% 4419
2023
Q1 		$525K Sell
72,157
-6,362
-8% -$27.8K ﹤0.01% 4517
2022
Q4 		$260K Sell
78,519
-142
-0.2% -$546 ﹤0.01% 4781
2022
Q3 		$389K Sell
78,661
-242
-0.3% -$1.71K ﹤0.01% 4797
2022
Q2 		$596K Sell
78,903
-6,316
-7% -$61K ﹤0.01% 4718
2022
Q1 		$1.36M Buy
85,219
+314
+0.4% +$4.16K ﹤0.01% 4553
2021
Q4 		$1.57M Sell
84,905
-643
-0.8% -$17.4K ﹤0.01% 4497
2021
Q3 		$2.62M Buy
85,548
+6,812
+9% +$269K ﹤0.01% 4210
2021
Q2 		$4.32M Sell
78,736
-110,386
-58% -$6.13M ﹤0.01% 3936
2021
Q1 		$11.2M Buy
189,122
+15,104
+9% +$993K ﹤0.01% 3498
2020
Q4 		$6.53M Sell
174,018
-22,757
-12% -$851K ﹤0.01% 3579
2020
Q3 		$10.6M Sell
196,775
-12,341
-6% -$2.23M ﹤0.01% 3194
2020
Q2 		$52.6M Buy
209,116
+16,701
+9% +$3.37M ﹤0.01% 2220
2020
Q1 		$30.2M Buy
192,415
+12,008
+7% +$2.03M ﹤0.01% 2378
2019
Q4 		$29.6M Sell
180,407
-178
-0.1% -$26.3K ﹤0.01% 2667
2019
Q3 		$26.4M Buy
180,585
+4,431
+3% +$772K ﹤0.01% 2661
2019
Q2 		$36.6M Buy
176,154
+8,456
+5% +$1.81M ﹤0.01% 2508
2019
Q1 		$35M Sell
167,698
-3,632
-2% -$801K ﹤0.01% 2485
2018
Q4 		$30M Sell
171,330
-2,675
-2% -$534K ﹤0.01% 2511
2018
Q3 		$39.4M Buy
174,005
+41,884
+32% +$6.77M ﹤0.01% 2509
2018
Q2 		$20M Buy
132,121
+10,502
+9% +$1.91M ﹤0.01% 2850
2018
Q1 		$22.3M Buy
121,619
+1,790
+1% +$402K ﹤0.01% 2704
2017
Q4 		$25.5M Buy
119,829
+33,226
+38% +$7.11M ﹤0.01% 2658
2017
Q3 		$18.6M Buy
86,603
+4,696
+6% +$919K ﹤0.01% 2850
2017
Q2 		$15.5M Buy
81,907
+59,726
+269% +$11.7M ﹤0.01% 2922
2017
Q1 		$5.49M Buy
+22,181
New +$5.44M ﹤0.01% 3359

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

BlackRock's CRBP Position: Q2 2026 in Review

BlackRock increased its Corbus Pharmaceuticals (CRBP) stake by 390% in Q2 2026, buying an estimated $10M and bringing the position to 1,331,135 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

BlackRock first reported a position in CRBP in Q1 2017 and has held it in 38 quarters since. The position peaked at $52.6M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • BlackRock held 1,331,135 shares of Corbus Pharmaceuticals worth $12.5M as of Q2 2026.
  • BlackRock bought 1,059,499 Corbus Pharmaceuticals shares in Q2 2026, an estimated $10M.
  • Corbus Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3560 holding.
  • BlackRock first reported a position in Corbus Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
  • BlackRock's Corbus Pharmaceuticals position peaked at $52.6M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.